Evidence map›Paper›PMID 26468528›Full record

ArticleJournal of virology2016

Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival.

Italo Tempera, Alessandra De Leo, Andrew V Kossenkov, Matteo Cesaroni, Hui Song, Noor Dawany, Louise Showe, Fang Lu, Priyankara Wikramasinghe, Paul M Lieberman

Abstract read
In one paragraph

Article in Journal of virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
2.9field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Chromatin Control of EBV Infection and Latency.Current topics in microbiology and immunology · 2025
    Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. The Molecular and Biological Function of MEF2D in Leukemia.Advances in experimental medicine and biology · 2024
    Review
  17. Article
  18. Article
  19. Article
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Italo TemperaFels Cancer Center, Temple University, Philadelphia, Pennsylvania, USA.
Alessandra De LeoThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Andrew V KossenkovThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Matteo CesaroniFels Cancer Center, Temple University, Philadelphia, Pennsylvania, USA.
Hui SongThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Noor DawanyThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Louise ShoweThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Fang LuThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Priyankara WikramasingheThe Wistar Institute, Philadelphia, Pennsylvania, USA.
Paul M LiebermanThe Wistar Institute, Philadelphia, Pennsylvania, USA Lieberman@wistar.org.
The Wistar Institute · USTemple University · US

Funding

WORD PROCESSING CENTER--COREP30CA006927 · NCI · RESEARCH INST OF FOX CHASE CAN CTR · PI Margaret von Mehren · 1985 to 2026
$138.8M
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9M
Regulation of Epstein-Barr Virus LatencyR01CA093606 · NCI · WISTAR INSTITUTE · PI LIEBERMAN, PAUL M. · 2002 to 2022
$6.7M
Epigenetic Regulation of Epstein-Barr Virus Latency ProgramsR01DE017336 · NIDCR · WISTAR INSTITUTE · PI PAUL M. LIEBERMAN · 2005 to 2026
$6.5M
NCI NIH HHS CA093606NCI NIH HHS P30 CA006927NCI NIH HHS P30 CA010815NCI NIH HHS P30 CA10815NCI NIH HHS R01 CA093606NIDCR NIH HHS DE 017336NIDCR NIH HHS R01 DE017336
6 · The paper itself

Abstract

unlabelledEpstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) is the EBV-encoded nuclear antigen and sequence-specific DNA binding protein required for viral origin binding and episome maintenance during latency. EBNA1 can also bind to numerous sites in the cellular genome and can provide a host cell survival function, but it is not yet known how EBNA1 sequence-specific binding is responsible for host cell survival. Here, we integrate EBNA1 chromatin immunoprecipitation sequencing (ChIP-Seq) with transcriptome sequencing (RNA-Seq) after EBNA1 depletion to identify cellular genes directly regulated by EBNA1 that are also essential for B-cell survival. We first compared EBNA1 ChIP-Seq patterns in four different EBV-positive cell types, including Burkitt lymphoma (BL) cells, nasopharyngeal carcinoma (NPC) cells, and lymphoblastoid cell lines (LCLs). EBNA1 binds to ~1,000 sites that are mostly invariant among cell types and share a consensus recognition motif. We found that a large subset of EBNA1 binding sites are located proximal to transcription start sites and correlate genome-wide with transcription activity. EBNA1 bound to genes of high significance for B-cell growth and function, including MEF2B, IL6R, and EBF1. EBNA1 depletion from latently infected LCLs results in the loss of cell proliferation and the loss of gene expression for some EBNA1-bound genes, including MEF2B, EBF1, and IL6R. Depletion of MEF2B, EBF1, or IL6R partially phenocopies EBNA1 depletion by decreasing the cell growth and viability of cells latently infected with EBV. These findings suggest that EBNA1 binds to a large cohort of cellular genes important for cell viability and implicates EBNA1 as a critical regulator of transcription of host cell genes important for enhanced survival of latently infected cells. IMPORTANCE: Epstein-Barr virus (EBV) latent infection is responsible for a variety of lymphoid and epithelial cell malignancies. EBNA1 is the EBV-encoded nuclear antigen that is consistently expressed in all EBV-associated cancers. EBNA1 is known to provide a host cell survival function, but the mechanism is not known. EBNA1 is a sequence-specific binding protein important for viral genome maintenance during latency. Here, by integrating ChIP-Seq and RNA-Seq, we demonstrate that EBNA1 binds directly to the promoter regulatory regions and upregulates the transcription of host genes that are important for the survival of EBV-infected cells. Identification of EBNA1 target genes provides potential new targets for therapeutic intervention in EBV-associated disease.

Indexed as

Cell ProliferationB-LymphocytesCell LineChromatin ImmunoprecipitationDNA-Binding ProteinsEpstein-Barr Virus Nuclear AntigensGene Expression ProfilingHerpesvirus 4, HumanHost-Pathogen InteractionsHumansMEF2 Transcription FactorsProtein BindingReceptors, Interleukin-6Sequence Analysis, DNATrans-ActivatorsDNA-Binding ProteinsEBF1 protein, humanEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensIL6R protein, humanMEF2B protein, humanMEF2 Transcription FactorsReceptors, Interleukin-6Trans-Activators

Identifiers

PMID26468528
PMCPMC4702570
OpenAlexW2338055556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.